Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest David Newsome Stories

2013-05-13 08:28:29

BIRMINGHAM, Ala., May 13, 2013 /PRNewswire/ -- The results of the second largest ophthalmic study in history were released on May 5, 2013 by the National Eye Institute (NEI) and confirms that Macular Health, LLC, a Birmingham, Ala.,-based company producing ophthalmic nutraceuticals, has had the ideal formulated product to combat Age-Related Macular Degeneration (AMD) since 2003. Macular Health's original formulation was modeled after the results of the largest ophthalmic study ever...

2011-02-27 05:00:00

ANN ARBOR, Mich., Feb. 27, 2011 /PRNewswire/ -- With deep regret, Adeona Pharmaceuticals, Inc. (Amex: AEN), announced today the passing of its Senior Vice President of Research & Development, David A. Newsome, M.D. Dr. Newsome invented and developed ZincMonoCysteine and was the first person to pioneer and demonstrate the benefits of oral high dose zinc therapy in age-related macular degeneration, the leading cause of blindness in older Americans. Oral high dose zinc containing...

2010-09-23 05:00:00

ANN ARBOR, Mich., Sept. 23 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN) announced today that it will host an investor day luncheon presentation at 12 Noon Eastern Time on Wednesday, September 29, 2010, in New York City. The keynote speaker will be David A. Newsome, M.D., FARVO, Adeona's Senior Vice President of Research and Development. Dr. Newsome has spent over a decade in clinical and laboratory research at the National Eye Institute, part of the National Institutes of...

2010-06-07 05:00:00

ANN ARBOR, Mich., June 7 /PRNewswire-FirstCall/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN) announced the completion of 50% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2). The CopperProof-2 study represents the first controlled clinical study of oral zinc cysteine for the dietary management of Alzheimer's disease and mild cognitive impairment. Part 2 of the...

2008-07-10 09:01:29

Pipex Pharmaceuticals has announced positive results from a double-blind, placebo-controlled clinical trial for the treatment of dry age-related macular degeneration with oral Zinthionein. Zinthionein capsules (25mg capsules twice daily) were compared to placebo capsules twice daily on a 1:1 randomization scheme in a prospective, randomized, double-blind, placebo-controlled trial involving a total of 80 dry age-related macular degeneration (AMD) patients for period of six months at a single...